Ghent University Academic Bibliography

Advanced

Results of a patient survey for an implantable neurostimulator to treat migraine headaches

Koen Paemeleire UGent and Amy Goodman (2012) JOURNAL OF HEADACHE AND PAIN. 13(3). p.239-241
abstract
Migraine attacks are believed to involve activation of the trigeminovascular system and trigeminal-parasympathetic reflex, which is mediated through the sphenopalatine ganglion (SPG). An implantable SPG neurostimulator has been developed to apply on-demand SPG stimulation for the treatment of severe primary headache. The neurostimulator is implanted via an oral incision and placed along the maxilla, with the lead placed at the SPG. The neurostimulator contains no battery and is powered and controlled via a handheld remote controller. The potential interest of patients with high-frequency, high-disability migraine in having a SPG neurostimulator implanted to treat migraine is unknown. We aimed to evaluate patient interest to undergo such an implantation procedure and to participate in a clinical investigation of on-demand SPG stimulation for migraine by conducting a survey at the Ghent University Hospital in 41 migraineurs. Seventy-seven percent (77%) of subjects expressed an interest in participating in a clinical investigation requiring implantation of a SPG neurostimulator when headache frequency and severity were considered and 69% when pain relief experienced with current migraine treatment was considered. Preventive and acute medications were used in 64 and 95% of the subjects, respectively, and provided a reported reduction of headache frequency, duration and pain. However, acute medications were frequently associated with headache recurrence and bothersome side effects. Results indicate that a majority of high-frequency, high-disability migraineurs, many of whom achieve pain relief with their current medications, have an interest in participating in a clinical investigation of an implantable SPG neurostimulator for the treatment of migraine headache.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Migraine, Sphenopalatine ganglion (SPG), Headache, Neuromodulation, Neurostimulation, SPHENOPALATINE GANGLION, ELECTRICAL-STIMULATION, CLUSTER HEADACHE
journal title
JOURNAL OF HEADACHE AND PAIN
J. Headache Pain
volume
13
issue
3
pages
239 - 241
Web of Science type
Article
Web of Science id
000302174800007
JCR category
CLINICAL NEUROLOGY
JCR impact factor
2.779 (2012)
JCR rank
68/190 (2012)
JCR quartile
2 (2012)
ISSN
1129-2369
DOI
10.1007/s10194-012-0430-0
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2116931
handle
http://hdl.handle.net/1854/LU-2116931
date created
2012-05-29 14:26:52
date last changed
2012-06-01 11:44:29
@article{2116931,
  abstract     = {Migraine attacks are believed to involve activation of the trigeminovascular system and trigeminal-parasympathetic reflex, which is mediated through the sphenopalatine ganglion (SPG). An implantable SPG neurostimulator has been developed to apply on-demand SPG stimulation for the treatment of severe primary headache. The neurostimulator is implanted via an oral incision and placed along the maxilla, with the lead placed at the SPG. The neurostimulator contains no battery and is powered and controlled via a handheld remote controller. The potential interest of patients with high-frequency, high-disability migraine in having a SPG neurostimulator implanted to treat migraine is unknown. We aimed to evaluate patient interest to undergo such an implantation procedure and to participate in a clinical investigation of on-demand SPG stimulation for migraine by conducting a survey at the Ghent University Hospital in 41 migraineurs. Seventy-seven percent (77\%) of subjects expressed an interest in participating in a clinical investigation requiring implantation of a SPG neurostimulator when headache frequency and severity were considered and 69\% when pain relief experienced with current migraine treatment was considered. Preventive and acute medications were used in 64 and 95\% of the subjects, respectively, and provided a reported reduction of headache frequency, duration and pain. However, acute medications were frequently associated with headache recurrence and bothersome side effects. Results indicate that a majority of high-frequency, high-disability migraineurs, many of whom achieve pain relief with their current medications, have an interest in participating in a clinical investigation of an implantable SPG neurostimulator for the treatment of migraine headache.},
  author       = {Paemeleire, Koen and Goodman, Amy},
  issn         = {1129-2369},
  journal      = {JOURNAL OF HEADACHE AND PAIN},
  keyword      = {Migraine,Sphenopalatine ganglion (SPG),Headache,Neuromodulation,Neurostimulation,SPHENOPALATINE GANGLION,ELECTRICAL-STIMULATION,CLUSTER HEADACHE},
  language     = {eng},
  number       = {3},
  pages        = {239--241},
  title        = {Results of a patient survey for an implantable neurostimulator to treat migraine headaches},
  url          = {http://dx.doi.org/10.1007/s10194-012-0430-0},
  volume       = {13},
  year         = {2012},
}

Chicago
Paemeleire, Koen, and Amy Goodman. 2012. “Results of a Patient Survey for an Implantable Neurostimulator to Treat Migraine Headaches.” Journal of Headache and Pain 13 (3): 239–241.
APA
Paemeleire, K., & Goodman, A. (2012). Results of a patient survey for an implantable neurostimulator to treat migraine headaches. JOURNAL OF HEADACHE AND PAIN, 13(3), 239–241.
Vancouver
1.
Paemeleire K, Goodman A. Results of a patient survey for an implantable neurostimulator to treat migraine headaches. JOURNAL OF HEADACHE AND PAIN. 2012;13(3):239–41.
MLA
Paemeleire, Koen, and Amy Goodman. “Results of a Patient Survey for an Implantable Neurostimulator to Treat Migraine Headaches.” JOURNAL OF HEADACHE AND PAIN 13.3 (2012): 239–241. Print.